Human cell-based anti-inflammatory effects of rosiglitazone.

Mariangela Sottili Tiziana Filardi Giulia Cantini Lorenzo Cosmi Susanna Morano Michaela Luconi Andrea Lenzi Clara Crescioli

Published in: Journal of endocrinological investigation (2021)

As the combination of Th1 biomarkers like CXCL10, IL-8, IL-6 with classical cardiovascular risk factors seems to improve the accuracy in predicting T2D and coronary events, future studies might be desirable to further investigate the anti-Th1 effect of RGZ.

Keyphrases

cardiovascular risk factors
endothelial cells
cardiovascular disease
metabolic syndrome
coronary artery disease
coronary artery
single cell
cell therapy
current status
pluripotent stem cells
bone marrow
stem cells
transcatheter aortic valve replacement